An improved whole cell pertussis vaccine with reduced content of endotoxin

• Published in: Human vaccines & immunotherapeutics 2013-02, Vol.9 (2), p.339-348
• Main Authors: Dias, Waldely, van der Ark, Arno A.J., Sakauchi, Maria Aparecida, Kubrusly, Flávia Saldanha, Prestes, Ana Fabíola R.O., Borges, Monamaris Marques, Furuyama, Noemi, Horton, Denise S.P.Q., Quintilio, Wagner, Antoniazi, Marta, Kuipers, Betsy, van der Zeijst, Bernard A.M., Raw, Isaias
• Format: Article
• Language: English
• Subjects: Animals; Bordetella pertussis; Drug Stability; endotoxicity; Endotoxins - analysis; Endotoxins - isolation & purification; Female; immunogenicity; lypo-oligosaccharide; Mice; Pertussis Vaccine - administration & dosage; Pertussis Vaccine - adverse effects; Pertussis Vaccine - chemistry; Pertussis Vaccine - immunology; pertussis vaccines; Rabbits; reactogenicity; Research Paper; safety; Vaccine Potency
• ISSN: 2164-5515; 2164-554X
• DOI: 10.4161/hv.22847

An improved whole cell pertussis vaccine, designated as Plow, which is low in endotoxicity due to a chemical extraction of lipo-oligosaccharide (LOS) from the outer membrane, was evaluated for safety, immunogenicity and potency, comparatively to a traditional whole cell pertussis vaccine. Current whole cell pertussis vaccines are effective but contain large quantities of endotoxin and consequently display local and systemic adverse reactions after administration. Endotoxin is highly inflammatory and contributes considerably to the reactogenicity as well as the potency of these vaccines. In contrast, acellular pertussis vaccines hardly contain endotoxin and are significantly less reactogenic, but their elevated costs limit their global use, especially in developing countries. In this paper, bulk products of Plow and a traditional whole cell vaccine, formulated as plain monocomponents or combined with diphtheria and tetanus toxoids (DTPlow or DTP, respectively) were compared by in vitro and in vivo assays. Chemical extraction of LOS resulted in a significant decrease in endotoxin content (20%) and a striking decline in endotoxin related toxicity (up to 97%), depending on the used in vitro or in vivo test. The LOS extraction did not affect the integrity of the product and, more importantly, did not affect the potency and/or stability of DTPlow. Moreover, hardly any differences in antibody and T-cell responses were observed. The development of Plow is a significant improvement regarding the endotoxicity of whole cell pertussis vaccines and therefore a promising and affordable alternative to currently available whole cell or acellular pertussis vaccines for developing countries.